- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Progenics Pharmaceuticals Inc
+ Add to WatchlistPGNX:US
4.0100 USD 0.1000 2.56%As of 12:26:52 ET on 05/23/2013.
Snapshot for Progenics Pharmaceuticals Inc (PGNX)
| Open: | 3.8600 | Day's Range: | 3.7700 - 4.0600 | Volume: | 97,573 |
|---|---|---|---|---|---|
| Previous Close: | 3.9100 | 52wk Range: | 1.4100 - 11.0000 | 1-Yr Rtn: | -49.37% |
Key Statistics for PGNX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.8500 |
| Est. EPS (USD) (12/2013) | -0.9450 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 199.56 |
| Shares Outstanding (M) | 51.04 |
| 30 Day Average Volume | 326,771 |
| Price/Book (mrq) | 3.0415 |
| Price/Sale (ttm) | 10.9076 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/09/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for PGNX
Company Profile & Key Executives for PGNX
Progenics Pharmaceuticals, Inc. is a biopharmaceutical company. The Company develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Progenics' principal programs are directed toward supportive care, virology (human immunodeficiency virus and hepatitis C virus infections), and oncology.
| Mark Robert BakerChief Executive Officer | Nitya G RaySenior VP:Manufacturing |
| Robert J IsraelSenior VP:Medical Affairs | William C OlsonSenior VP:Research & Dev |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
PGNX News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page